Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 27

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

An open-label pilot study of combined augmentation with creatine monohydrate and 5-hydroxytryptophan for selective serotonin reuptake inhibitor- or serotonin-norepinephrine reuptake inhibitor-resistant depression in adult women

Kious, Brent M., Sabic, Hana, Sung, Young-Hoon, Kondo, Douglas G., Renshaw, Perry·2017·Journal of Clinical Psychopharmacology
DOI 10.1097/jcp.0000000000000754
Open this paper in CoChat — free account

Abstract

Purpose: Many women with major depressive disorder (MDD) respond inadequately to standard treatments. Augmentation of conventional antidepressants with creatine monohydrate and 5-hydroxytryptophan (5-HTP) could correct deficits in serotonin production and brain bioenergetics associated with depression in women, yielding synergistic benefit. We describe an open-label study of 5-HTP and creatine augmentation in women with MDD who had failed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) monotherapy. Methods: Fifteen women who were adequately adherent to an SSRI or SNRI and currently experiencing MDD, with a 17-item Hamilton Depression Rating Scale (HAM-D) score of 16 or higher, were treated with 5 g of creatine monohydrate daily and 100 mg of 5-HTP twice daily for 8 weeks, with 4 weeks of posttreatment follow-up. The primary outcome was change in mean HAM-D scores. Results: Mean HAM-D scores declined from 18.9 (SD, 2.5) at pretreatment visits to 7.5 (SD, 4.4) (P < 0.00001), a decrease of 60%. Participants did not experience any serious treatment-related adverse events. Conclusions: Combination treatment with creatine and 5-HTP may represent an effective augmentation strategy for women with SSRI- or SNRI-resistant depression. Given the limitations of this small, open-label trial, future study in randomized, placebo-controlled trials is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000754

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 43

  1. 2005, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication, Arch Gen Psychiatry, 62, 593, 10.1001/archpsyc.62.6.593 · DOI · Paper page
  2. 2015, Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder, J Clin Psychiatry, 76, e809, 10.4088/JCP.14m09548 · DOI
  3. 1999, Depression in the workplace: effects on short-term disability, Health Aff (Millwood), 18, 163, 10.1377/hlthaff.18.5.163 · DOI · Paper page
  4. 2003, The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity, Int Rev Psychiatry, 15, 74, 10.1080/0954026021000045976 · DOI · Paper page
  5. 1988, Suicide attempts in the Epidemiologic Catchment Area Study, Yale J Biol Med, 61, 259
  6. 1997, Differences between males and females in rates of serotonin synthesis in human brain, Proc Natl Acad Sci U S A, 94, 5308, 10.1073/pnas.94.10.5308 · DOI · Paper page
  7. 2011, Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice, Pharmacol Biochem Behav, 99, 683, 10.1016/j.pbb.2011.06.020 · DOI
  8. 2015, Brain 5-HT deficiency increases stress vulnerability and impairs antidepressant responses following psychosocial stress, Proc Natl Acad Sci U S A, 112, 2557, 10.1073/pnas.1416866112 · DOI
  9. 2013, Chronic SSRI treatment exacerbates serotonin deficiency in humanized tph2 mutant mice, ACS Chem Neurosci, 4, 84, 10.1021/cn300127h · DOI
  10. 1993, Regulation of serotonin synthesis, Prog Biophys Mol Biol, 60, 1, 10.1016/0079-6107(93)90009-9 · DOI
  11. 1998, 5-Hydroxytryptophan: a clinically-effective serotonin precursor, Altern Med Rev, 3, 271
  12. 2006, Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan, Pharmacol Ther, 109, 325, 10.1016/j.pharmthera.2005.06.004 · DOI · Paper page
  13. 2016, SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept, Neuropsychopharmacology, 41, 2324, 10.1038/npp.2016.35 · DOI
  14. 1991, The serotonin syndrome, Am J Psychiatry, 148, 705, 10.1176/ajp.148.6.705 · DOI · Paper page
  15. 1983, Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study, Int J Clin Pharmacol Res, 3, 239
  16. 1982, Serotonin precursors in the treatment of depression, Adv Biochem Psychopharmacol, 34, 259
  17. 1980, l-5-hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with ‘therapy-resistant’ depressions, Neuropsychobiology, 6, 230, 10.1159/000117757 · DOI
  18. 1976, 5-hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study, Int Pharmacopsychiatry, 11, 8, 10.1159/000468207 · DOI
  19. 2008, Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder, Biol Psychiatry, 63, 1127, 10.1016/j.biopsych.2007.11.020 · DOI · Paper page
  20. 1997, Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study, Am J Psychiatry, 154, 116, 10.1176/ajp.154.1.116 · DOI
  21. 1998, 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients, Eur Arch Psychiatry Clin Neurosci, 248, 289, 10.1007/s004060050052 · DOI · Paper page
  22. 2003, Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate, Psychiatry Res, 123, 87, 10.1016/S0925-4927(03)00046-5 · DOI · Paper page
  23. 2011, Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study, J Affect Disord, 135, 354, 10.1016/j.jad.2011.07.010 · DOI · Paper page
  24. 2016, Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression, Amino Acids, 48, 1941, 10.1007/s00726-016-2194-3 · DOI · Paper page
  25. 2012, A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder, Am J Psychiatry, 169, 937, 10.1176/appi.ajp.2012.12010009 · DOI · Paper page
  26. 1994, The optimal dosing regimen for citalopram—a meta-analysis of nine placebo-controlled studies, Int Clin Psychopharmacol, 9, 35, 10.1097/00004850-199403001-00006 · DOI
  27. 2006, Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis, J Psychiatry Neurosci, 31, 122
  28. 1998, A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression, J Clin Psychiatry, 59, 116, 10.4088/JCP.v59n0305 · DOI
  29. 2006, Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range, J Psychiatr Res, 40, 337, 10.1016/j.jpsychires.2005.08.010 · DOI
  30. 1987, 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects, J Clin Psychopharmacol, 7, 127
  31. 1999, Long-term oral creatine supplementation does not impair renal function in healthy athletes, Med Sci Sports Exerc, 31, 1108, 10.1097/00005768-199908000-00005 · DOI · Paper page
  32. 2006, Risk assessment for creatine monohydrate, Regul Toxicol Pharmacol, 45, 245
  33. 2011, Post‐epidemic eosinophilia-myalgia syndrome associated with L‐tryptophan, Arthritis Rheum, 63, 3633, 10.1002/art.30514 · DOI
  34. 1997, Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data, Stat Med, 16, 2349, 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E · DOI
  35. 2002, Defining remission by cut off score on the MADRS: selecting the optimal value, J Affect Disord, 72, 177, 10.1016/S0165-0327(01)00451-7 · DOI · Paper page
  36. 2014, Inherited renal diseases, Curr Pediatr Rev, 10, 95, 10.2174/157339631002140513101755 · DOI
  37. 1998, ABC of oxygen: oxygen at high altitude, BMJ, 317, 1063, 10.1136/bmj.317.7165.1063 · DOI · Paper page
  38. 1986, Cardiovascular adaptation to exercise at high altitude, Exerc Sport Sci Rev, 14, 269
  39. 2013, Elevated incidence of suicide in people living at altitude, smokers and patients with chronic obstructive pulmonary disease and asthma: possible role of hypoxia causing decreased serotonin synthesis, J Psychiatry Neurosci, 38, 423, 10.1503/jpn.130002 · DOI
  40. 2011, Hypobaric hypoxia modulates brain biogenic amines and disturbs sleep architecture, Neurochem Int, 58, 112, 10.1016/j.neuint.2010.11.003 · DOI
  41. 2015, Antidepressant efficacy in a rodent model of hypoxia-related depression: do SSRIs lose efficacy at altitude?, Neuropsychopharmacology, 40, S272
  42. 2014, Effect of altitude on brain intracellular pH and inorganic phosphate levels, Psychiatry Res, 222, 149, 10.1016/j.pscychresns.2014.04.002 · DOI
  43. 2014, Neurochemical alterations in frontal cortex of the rat after one week of hypobaric hypoxia, Behav Brain Res, 263, 203, 10.1016/j.bbr.2014.01.027 · DOI

Cited by

See all 27

Metadata

Authors
Kious, B. M., Sabic, H., Sung, Y.-H., Kondo, D. G., & Renshaw, P.
Affiliations
From the *Department of Psychiatry and †Brain Institute, University of Utah; and ‡Veterans Integrated Service Network 19 Mental Illness Research Education Clinical, Centers of Excellence, Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT.
Venue
Journal of Clinical Psychopharmacology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2017-10
Volume
37
Issue
5
Pages
578-583
ISSN
  • 1533-712X
  • 0271-0749
DOI
10.1097/jcp.0000000000000754
Cited by
27
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An open-label pilot study of combined augmentation with creatine monohydrate and 5-hydroxytryptophan for selective serotonin reuptake inhibitor- or serotonin-norepinephrine reuptake inhibitor-resistant depression in adult women. https://app.cochat.ai/papers/10.1097/jcp.0000000000000754
The paper
Kious, B. M., Sabic, H., Sung, Y.-H., Kondo, D. G., & Renshaw, P. (2017). An open-label pilot study of combined augmentation with creatine monohydrate and 5-hydroxytryptophan for selective serotonin reuptake inhibitor- or serotonin-norepinephrine reuptake inhibitor-resistant depression in adult women. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.